Literature DB >> 3700610

Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

M L Clements, B R Murphy.   

Abstract

An enzyme-linked immunosorbent assay was used to measure nasal-wash and serum isotype-specific hemagglutinin antibody responses in 109 seronegative (hemagglutination-inhibiting titer less than or equal to 1:8) adults vaccinated intranasally with live attenuated A/Washington/897/80 (H3N2) or A/California/10/78 (H1N1) cold-adapted (ca) virus or with licensed subvirion vaccine subcutaneously. Live and inactivated virus elicited serum immunoglobulin A (IgA) responses in 83 and 96% of vaccinees, respectively, and elicited serum IgG responses in 72 and 100% of vaccinees. Inactivated virus induced higher titers of serum antibodies than did live virus and stimulated a nasal-wash IgG response more often than did live virus (94 versus 59%, P less than 0.01). In contrast, only 38% of inactivated virus vaccinees had local IgA responses compared with 83% of live virus vaccinees. Serum IgA and IgG and nasal IgG antibody titers remained elevated above prevaccination levels for at least 6 months in most of the live and inactivated vaccine responders, but the mean level of local IgA antibody induced by infection with live virus vaccine, in particular, decreased substantially. Considered in the context of previous work, the finding that live virus vaccine induced relatively long-lasting antibody in both local and serum compartments suggested that this vaccine may be a suitable alternative to inactivated vaccine for use in healthy persons.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700610      PMCID: PMC268574          DOI: 10.1128/jcm.23.1.66-72.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Revised (1972-1973) bivalent influenza vaccine. Serum and nasal antibody responses to parenteral vaccination.

Authors:  R P Wenzel; J O Hendley; M A Sande; J M Gwaltney
Journal:  JAMA       Date:  1973-10-22       Impact factor: 56.272

2.  Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital.

Authors:  T W Hoskins; J R Davies; A J Smith; C L Miller; A Allchin
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

Review 3.  Mucosal immunology.

Authors:  J Bienenstock; A D Befus
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

4.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

5.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06

6.  Immunity to influenza in ferrets. XIV: Comparative immunity following infection or immunization with live or inactivated vaccine.

Authors:  R J Fenton; A Clark; C W Potter
Journal:  Br J Exp Pathol       Date:  1981-06

7.  Local and systemic immunity to influenza infections in ferrets.

Authors:  W H Barber; P A Small
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

8.  Protection of infants from infection with influenza A virus by transplacentally acquired antibody.

Authors:  J M Puck; W P Glezen; A L Frank; H R Six
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.

Authors:  T A Brown; B R Murphy; J Radl; J J Haaijman; J Mestecky
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

10.  Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis.

Authors:  R Ramphal; R C Cogliano; J W Shands; P A Small
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more
  80 in total

1.  Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.

Authors:  B Liang; L Hyland; S Hou
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests.

Authors:  A M Iorio; T Zei; M Neri; L Campitelli; M R Castrucci; I Donatelli
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

Review 3.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

5.  Repeated influenza vaccination of healthy children and adults: borrow now, pay later?

Authors:  F Carrat; A Lavenu; S Cauchemez; S Deleger
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

6.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 7.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

Review 9.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.